Studies related to Serum TGF-β and Vitamin E

Plasma Transforming Growth Factor-beta1 Level And Efficacy Of Alpha-tocopherol In Patients With Non-alcoholic Steatohepatitis: A Pilot Study

Effect Decrease
Trial Design Non-controlled trial
Trial Length 6+ Months
Number of Subjects 22
Sex Both Genders
Age Range 30-44
Body Types Overweight
Notes for this study:
Supplementation of alpha-tocopherol (300mg) daily for one year in persons with NAFLD after a six month introductory period (lifestyle and diet modification) noted that the addition of vitamin E was able to reduce circulating ALT in persons with NAFLD but not steatohepatitis although fibrotic, inflammation, and steatitis scores of those with steatohepatitis were improved with vitamin E; both groups experienced a reduction in circulating TGF-b.